Saito Biological: Beta Methasone Chemical Active Pharmaceutical Ingredient Marketing Application Approved

2026-03-17 17:31:47

People’s Financial News, March 16 — Saito Biotech (300583) announced on March 16 that its controlling subsidiary, Shandong Surui Pharmaceutical Co., Ltd., recently received the “Approval Notice for the Listing of Betamethasone as a Chemical Raw Material Drug” issued by the National Medical Products Administration. Betamethasone is a hormone-based medication primarily used to treat allergies and autoimmune inflammatory conditions. It helps reduce inflammation, prevents tissue damage caused by excessive inflammation, and suppresses overreaction of the immune system and allergic reactions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.